Physician profile
Howard E Feingold
NPI 1649221672
$4,148.26
in general payments reported to CMS, 2019-2025
31 companies · $493 in 2025
The $493 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $358 · 2020: $519 · 2021: $713 · 2022: $759 · 2023: $628 · 2024: $680 · 2025: $493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,800.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $953.48 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $536.13 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $395.62 | 2019-2025 | |
| Pfizer INC. | $340.80 | 2019-2025 | |
| Lilly USA, LLC | $288.20 | 2020-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $277.35 | 2019-2025 | Evenity, Prolia, Otezla |
| Amarin Pharma, INC. | $256.47 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $178.86 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $118.88 | 2019-2022 | |
| Exact Sciences Corporation | $115.45 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $105.84 | 2020-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $93.75 | 2019-2025 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $66.04 | 2019-2021 | |
| Edwards Lifesciences Corporation | $40.07 | 2024 | Sapien 3 Ultra Resilia |
| Biohaven Pharmaceuticals, INC. | $39.94 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $31.19 | 2022 | |
| Idorsia Pharmaceuticals US INC | $29.93 | 2023-2024 | Quviviq |
| Insmed, INC. | $26.00 | 2025 | Brinsupri, Arikayce |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.39 | 2024 | |
| Dexcom, INC. | $23.39 | 2024 | Dexcom G6 Transmitter |
| Lucid Diagnostics INC. | $22.80 | 2023 | |
| Tolmar Pharmaceuticals, INC. | $22.16 | 2022 | |
| Astellas Pharma US INC | $21.75 | 2021 | |
| Abbott Laboratories | $21.29 | 2023 | Freestyle Libre 3 |
| Nevro Corp. | $19.94 | 2023 | Senza |
| Eisai INC. | $19.18 | 2020 | |
| Esperion Therapeutics, INC. | $18.47 | 2020 | |
| Ibsa Pharma INC. | $17.50 | 2021 | |
| Grt US Holding, INC. | $15.06 | 2022 | |
| Tolmar, INC. | $14.37 | 2023 | |
| Radius Health, INC. | $12.96 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Feingold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.